-
公开(公告)号：US20130267518A1
公开(公告)日：2013-10-10
申请号：US13910769
申请日：2013-06-05
Applicant: Novartis AG
Inventor： Kamlesh Jagdis Bala , Catherine Leblanc , David Andrew Sandham , Katherine Louise Turner , Simon James Watson , Lyndon Nigel Brown , Brian Cox
IPC: C07D471/04
CPC classification number: C07D471/04 , A61K31/437 , A61K45/06
Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
Abstract translation: 根据本发明，提供游离或盐形式的式（I）化合物，其中R 1，R 2，R 3，R 4，R 5，R 6，Q，W，X，m，n和p如说明书中所述， 制备它们的过程，以及它们作为药物的用途。
-
公开(公告)号：US10195181B2
公开(公告)日：2019-02-05
申请号：US15184730
申请日：2016-06-16
Applicant: Novartis AG
Inventor： Kamlesh Jagdis Bala , Andrew Brearley , James Dale , Anne-Marie Edwards , Mahbub Ahmed , David Porter , Robert Alexander Pulz , Lisa Ann Rooney , David Andrew Sandham , Duncan Shaw , Nichola Smith , Jessica Louise Taylor , Roger John Taylor , Thomas Josef Troxler , Joe Wrigglesworth
IPC: A61K31/422 , C07D413/14 , A61K31/4155 , C07D413/12
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
-
公开(公告)号：US08791256B2
公开(公告)日：2014-07-29
申请号：US13910769
申请日：2013-06-05
Applicant: Novartis AG
Inventor： Kamlesh Jagdis Bala , Catherine Leblanc , David Andrew Sandham , Katharine Louise Turner , Simon James Watson , Lyndon Nigel Brown , Brian Cox
IPC: C07D471/04
CPC classification number: C07D471/04 , A61K31/437 , A61K45/06
Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.
Abstract translation: 根据本发明，提供游离或盐形式的式（I）化合物，其中R 1，R 2，R 3，R 4，R 5，R 6，Q，W，X，m，n和p如说明书中所述， 制备它们的过程，以及它们作为药物的用途。
-
公开(公告)号：US20200277378A1
公开(公告)日：2020-09-03
申请号：US16764102
申请日：2018-11-16
Applicant: Novartis AG
Inventor： Catherine Anne Sabatos-Peyton , Jennifer Marie Mataraza , Kenzie MacIsaac , Eunice Kwak , Jason Faris , Glenn Dranoff , Marion Wiesmann , Fiona Sharp , Adam Crystal , John Scott Cameron , Robert Martin Strieter , Lilli Petruzzelli , Shamsah Kazani , David Andrew Sandham , Neil John Press , Keith Hoffmaster
Abstract: Combination therapies comprising PD-1 inhibitors and other therapeutic agents used to treat or prevent cancerous conditions and disorders as follow. Combination therapies of three agents which are a PD-1 inhibitor, a CXCR2 inhibitor and a CSF-1/1R binding agent for treating a pancreatic cancer or a colorectal cancer. Combination therapies of three agents which are a PD-1 inhibitor, a CXCR2 inhibitor and an inhibitor of either TIM-3, C-MET or A2aR for treating a pancreatic cancer or a colorectal cancer. Combination therapies of three agents which are a PD-1 inhibitor, a LAG-3 inhibitor and (i) an inhibitor of either TGF-beta, TIM-3, C-MET, IL-1b or MEK or (ii) a GITR agonist or (iii) an A2aR antagonist or (iv) a CSF-1/1R binding agent for treating a breast cancer. Combination therapies of two agents which are a PD-1 inhibitor and a CXCR2 inhibitor for treating a pancreatic cancer, a colorectal cancer, a lung cancer or a breast cancer.
-
公开(公告)号：US10183025B2
公开(公告)日：2019-01-22
申请号：US15673155
申请日：2017-08-09
Applicant: Novartis AG
Inventor： David Beattie , Urs Baettig , Darren Mark Le Grand , Andrew Stuart Lister , Jeffrey McKenna , David William Pearce , David Andrew Sandham , Oliver Ross Steward , Christopher Thomson
IPC: A61K31/445 , A61K31/551 , C07D403/12 , C07D401/14 , C07D413/14 , A61K31/41 , A61K31/4245 , A61K31/427 , A61K31/5377 , A61K31/5513 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/14 , C07D407/12 , C07D413/10 , C07D413/12 , C07D417/10 , C07D417/14 , C07D257/04 , A61K45/06 , A61K31/45 , A61K31/496 , A61K31/504 , A61K31/439 , A61K31/454 , A61K31/4545 , A61K31/506 , C07D405/12 , C07D471/08
Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
-
Patent Agency Ranking
公开(公告)号：US09763957B2
公开(公告)日：2017-09-19
申请号：US14906161
申请日：2014-07-16
Applicant: Novartis AG
Inventor： David Beattie , Urs Baettig , Darren Mark Legrand , Andrew Stuart Lister , Jeffrey McKenna , David William Pearce , David Andrew Sandham , Oliver Ross Steward , Christopher Thomson
IPC: A61K31/445 , A61K31/551 , C07D403/12 , C07D401/14 , C07D413/14 , A61K31/41 , A61K31/4245 , A61K31/427 , A61K31/5377 , A61K31/5513 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/14 , C07D407/12 , C07D413/10 , C07D413/12 , C07D417/10 , C07D417/14 , C07D257/04 , A61K45/06 , A61K31/45 , A61K31/496 , A61K31/504 , A61K31/439 , A61K31/454 , A61K31/4545 , A61K31/506 , C07D405/12 , C07D471/08
CPC classification number: A61K31/551 , A61K31/41 , A61K31/4245 , A61K31/427 , A61K31/439 , A61K31/445 , A61K31/45 , A61K31/454 , A61K31/4545 , A61K31/496 , A61K31/504 , A61K31/506 , A61K31/5377 , A61K31/5513 , A61K45/06 , C07D257/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/12 , C07D407/12 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/10 , C07D417/14 , C07D471/08 , A61K2300/00
Abstract: The present invention relates to novel compounds that are autotaxin inhibitors, processes for their preparation, pharmaceutical compositions and medicaments containing them and to their use in diseases and disorders mediated by autotaxin.
-
公开(公告)号：US12157737B2
公开(公告)日：2024-12-03
申请号：US18319585
申请日：2023-05-18
Applicant: NOVARTIS AG
Inventor： Mallesh Bushaboina , Xin Chen , Atwood Kim Cheung , Andrew James Culshaw , Timothy Brian Hurley , Nancy Labbe-Giguere , Wolfgang Miltz , David Orain , Tajesh Patel , Srinivasan Rajagopalan , Till Roehn , David Andrew Sandham , Gebhard Thoma , Ritesh Bhanudasji Tichkule , Rudolf Wälchli
IPC: A61K31/438 , A61K31/506 , A61K45/06 , C07D471/10 , C07D519/00
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
-
公开(公告)号：US09403810B2
公开(公告)日：2016-08-02
申请号：US14711684
申请日：2015-05-13
Applicant: Novartis AG
Inventor： Kamlesh Jagdis Bala , Andrew Brearley , James Dale , Anne-Marie Edwards , Mahbub Ahmed , David Porter , Robert Alexander Pulz , Lisa Ann Rooney , David Andrew Sandham , Duncan Shaw , Nichola Smith , Jessica Louise Taylor , Roger John Taylor , Thomas Josef Troxler , Joe Wrigglesworth
IPC: C07D413/12 , C07D413/14 , A61K31/4155 , A61K31/422
CPC classification number: A61K31/422 , A61K31/4155 , C07D413/12 , C07D413/14 , A61K2300/00
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Abstract translation: 本发明提供式（I）化合物或其药学上可接受的盐; 制备本发明化合物的方法及其治疗用途。 本发明还提供药理活性剂和药物组合物的组合。
-
公开(公告)号：US11708366B2
公开(公告)日：2023-07-25
申请号：US17400458
申请日：2021-08-12
Applicant: Novartis AG
Inventor： Mallesh Bushaboina , Xin Chen , Atwood Kim Cheung , Andrew James Culshaw , Timothy Brian Hurley , Nancy Labbe-Giguere , Wolfgang Miltz , David Orain , Tajesh Patel , Srinivasan Rajagopalan , Till Roehn , David Andrew Sandham , Gebhard Thoma , Ritesh Bhanudasji Tichkule , Rudolf Wälchli
IPC: C07D471/10 , A61K31/438 , A61K45/06 , C07D519/00
CPC classification number: C07D471/10 , A61K45/06 , C07D519/00
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;
wherein R1 R2, R4 and X1 are defined herein, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.-
公开(公告)号：US11672782B2
公开(公告)日：2023-06-13
申请号：US17089064
申请日：2020-11-04
Applicant: Novartis AG
Inventor： Kamlesh Jagdis Bala , Andrew Brearley , James Dale , Anne-Marie Edwards , Mahbub Ahmed , David Porter , Robert Alexander Pulz , Lisa Ann Rooney , David Andrew Sandham , Duncan Shaw , Nichola Smith , Jessica Louise Taylor , Roger John Taylor , Thomas Josef Troxler , Joe Wrigglesworth
IPC: A61K31/422 , A61K31/4155 , C07D413/12 , C07D413/14
CPC classification number: A61K31/422 , A61K31/4155 , C07D413/12 , C07D413/14 , A61K31/422 , A61K2300/00
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof;
a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.018 seconds)
